Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):1951–1957. doi: 10.1128/aac.36.9.1951

Adaptive resistance following single doses of gentamicin in a dynamic in vitro model.

M L Barclay 1, E J Begg 1, S T Chambers 1
PMCID: PMC192214  PMID: 1416886

Abstract

Adaptive resistance is a phenomenon recently described for Pseudomonas aeruginosa and other gram-negative bacilli following exposure to aminoglycoside antibiotics. It is a reversible form of resistance which develops within 1 to 2 h of initial exposure to an aminoglycoside and disappears several hours after removal of the antibiotic. We investigated adaptive resistance in P. aeruginosa ATCC 27853 following single doses of gentamicin by using a dynamic in vitro model which mimics in vivo pharmacokinetics. The initial peak gentamicin concentrations were 2.5, 8, and 25 mg/liter, and these were followed by an exponential decay in the concentration, with a half-life of 2.5 h. The degree of adaptive resistance was greater and the duration was longer with higher initial gentamicin concentrations. Maximal adaptive resistance occurred between 2 and 10 h following 8 mg/liter and between 2 and 16 h following 25 mg/liter. Full recovery of susceptibility occurred at approximately 36, 39, and 43 h following 2.5, 8, and 25 mg/liter, respectively, at which times the gentamicin concentrations were extremely low. Longer dosing intervals for aminoglycosides may improve efficacy by allowing time for adaptive resistance to resolve.

Full text

PDF
1951

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelov A., Barrientos G., Gutensohn G., Lenzner A. Die tägliche Einmaldosis von Gentamicin bei der Behandlung von Harnwegsinfektionen. MMW Munch Med Wochenschr. 1980 Feb 8;122(6):212–214. [PubMed] [Google Scholar]
  2. Begg E. J., Peddie B. A., Chambers S. T., Boswell D. R. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother. 1992 Apr;29(4):427–433. doi: 10.1093/jac/29.4.427. [DOI] [PubMed] [Google Scholar]
  3. Bodey G. P., Middleman E., Umsawasdi T., Rodriguez V. Intravenous gentamicin therapy for infections in patients with cancer. J Infect Dis. 1971 Dec;124 (Suppl):S174–S179. doi: 10.1093/infdis/124.supplement_1.s174. [DOI] [PubMed] [Google Scholar]
  4. Bryan L. E. Two forms of antimicrobial resistance: bacterial persistence and positive function resistance. J Antimicrob Chemother. 1989 Jun;23(6):817–820. doi: 10.1093/jac/23.6.817. [DOI] [PubMed] [Google Scholar]
  5. Chamberland S., Malouin F., Rabin H. R., Schollaardt T., Parr T. R., Jr, Bryan L. E. Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. J Antimicrob Chemother. 1990 Jun;25(6):995–1010. doi: 10.1093/jac/25.6.995. [DOI] [PubMed] [Google Scholar]
  6. Chambers S. T., Peddie B. A., Robson R. A., Begg E. J., Boswell D. R. Antimicrobial effects of lomefloxacin in vitro. J Antimicrob Chemother. 1991 Apr;27(4):481–489. doi: 10.1093/jac/27.4.481. [DOI] [PubMed] [Google Scholar]
  7. Chan G. L. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP. 1989 Oct;23(10):788–794. doi: 10.1177/106002808902301010. [DOI] [PubMed] [Google Scholar]
  8. Craig W. A., Vogelman B. The postantibiotic effect. Ann Intern Med. 1987 Jun;106(6):900–902. doi: 10.7326/0003-4819-106-6-900. [DOI] [PubMed] [Google Scholar]
  9. Daikos G. L., Jackson G. G., Lolans V. T., Livermore D. M. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis. 1990 Aug;162(2):414–420. doi: 10.1093/infdis/162.2.414. [DOI] [PubMed] [Google Scholar]
  10. Daikos G. L., Lolans V. T., Jackson G. G. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother. 1991 Jan;35(1):117–123. doi: 10.1128/aac.35.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ericsson C. D., Fischer R. P., Rowlands B. J., Hunt C., Miller-Crotchett P., Reed L., 2nd Prophylactic antibiotics in trauma: the hazards of underdosing. J Trauma. 1989 Oct;29(10):1356–1361. [PubMed] [Google Scholar]
  12. Fan S. T., Lau W. Y., Teoh-Chan C. H., Lau K. F., Mauracher E. H. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother. 1988 Jul;22(1):69–74. doi: 10.1093/jac/22.1.69. [DOI] [PubMed] [Google Scholar]
  13. Frass M., Traindl O., Podolsky A., Leithner C., Graninger W. Vergleich der Einmalgabe von Netilmicin mit der Dreimalgabe bei Intensivpatienten. Wien Klin Wochenschr. 1991;103(4):101–104. [PubMed] [Google Scholar]
  14. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gilleland H. E., Jr Adaptive alterations in the outer membrane of gram-negative bacteria during human infection. Can J Microbiol. 1988 Apr;34(4):499–502. doi: 10.1139/m88-085. [DOI] [PubMed] [Google Scholar]
  16. Gilleland L. B., Gilleland H. E., Gibson J. A., Champlin F. R. Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. J Med Microbiol. 1989 May;29(1):41–50. doi: 10.1099/00222615-29-1-41. [DOI] [PubMed] [Google Scholar]
  17. Hollender L. F., Bahnini J., De Manzini N., Lau W. Y., Fan S. T., Hermansyur K., Benny P., Husni A. N., Sutjipto, Lorber R. R. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989 May;23(5):773–783. doi: 10.1093/jac/23.5.773. [DOI] [PubMed] [Google Scholar]
  18. Ibrahim S., Derde M. P., Kaufman L., Clerckx-Braun F., Jacqmin P., Brulein V., Donnez J., Tulkens P. M. Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease. Ren Fail. 1990;12(3):199–203. doi: 10.3109/08860229009065564. [DOI] [PubMed] [Google Scholar]
  19. Jackson G. G., Riff L. J. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis. 1971 Dec;124 (Suppl):S185–S191. doi: 10.1093/infdis/124.supplement_1.s185. [DOI] [PubMed] [Google Scholar]
  20. Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar]
  21. Kovarik J. M., Hoepelman I. M., Verhoef J. Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis. 1989 Sep;8(9):761–769. doi: 10.1007/BF02185842. [DOI] [PubMed] [Google Scholar]
  22. Maller R., Isaksson B., Nilsson L., Sörén L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother. 1988 Jul;22(1):75–79. doi: 10.1093/jac/22.1.75. [DOI] [PubMed] [Google Scholar]
  23. Mattie H., Craig W. A., Pechère J. C. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–293. doi: 10.1093/jac/24.3.281. [DOI] [PubMed] [Google Scholar]
  24. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  25. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  26. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nordström L., Lerner S. A. Single daily dose therapy with aminoglycosides. J Hosp Infect. 1991 Jun;18 (Suppl A):117–129. doi: 10.1016/0195-6701(91)90013-x. [DOI] [PubMed] [Google Scholar]
  28. Nordström L., Ringberg H., Cronberg S., Tjernström O., Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 1990 Jan;25(1):159–173. doi: 10.1093/jac/25.1.159. [DOI] [PubMed] [Google Scholar]
  29. Pechère J. C., Craig W. A., Meunier F. Once daily dosing of aminoglycoside: one step forward. J Antimicrob Chemother. 1991 May;27 (Suppl 100):149–152. doi: 10.1093/jac/27.suppl_c.149. [DOI] [PubMed] [Google Scholar]
  30. Pierre C., Blanchet F., Seta N., Chaigne P., Labarre C., Sterkers O., Amiel C., Carbon C. Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers. Clin Pharmacol Ther. 1988 Oct;44(4):458–466. doi: 10.1038/clpt.1988.180. [DOI] [PubMed] [Google Scholar]
  31. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar]
  32. Proctor L., Petty B., Thakor R., Lietman P., Glackin R., Shimizu H. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope. 1987 Dec;97(12):1443–1449. doi: 10.1288/00005537-198712000-00012. [DOI] [PubMed] [Google Scholar]
  33. Rotheram E. B., Jr Clinical response and peak concentrations of aminoglycosides. J Infect Dis. 1988 Feb;157(2):395–396. doi: 10.1093/infdis/157.2.395. [DOI] [PubMed] [Google Scholar]
  34. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar]
  35. Van der Auwera P., Meunier F., Ibrahim S., Kaufman L., Derde M. P., Tulkens P. M. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother. 1991 Apr;35(4):640–647. doi: 10.1128/aac.35.4.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yonovitz A., Fisch J. E. Circadian rhythm dependent kanamycin-induced hearing loss in rodents assessed by auditory brainstem responses. Acta Otolaryngol. 1991;111(6):1006–1012. doi: 10.3109/00016489109100749. [DOI] [PubMed] [Google Scholar]
  37. de Vries P. J., Verkooyen R. P., Leguit P., Verbrugh H. A. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):161–168. doi: 10.1007/BF01963832. [DOI] [PubMed] [Google Scholar]
  38. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES